BioSpace News Archive

DENTSPLY SIRONA Inc. announced that Eric K. Brandt, who has served as a Director on the Company’s Board of Directors for nearly twenty years and as Chairman of the Board for six years, has informed the Board of his intention to retire at the May 2024 annual meeting and that he will not be standing for re-election.

Orbis Medicines, a leader in oral macrocycle drug discovery, announces its launch with a €26 million financing led by global life sciences investor Novo Holdings and European life sciences venture firm Forbion.

Coave Therapeutics is delighted to announce that it is one of six organisations sharing $2.9 million in grants from the ALS Association that support the advancement of novel therapies for the treatment of amyotrophic lateral sclerosis.

Milestone® Pharmaceuticals Inc. announced the pricing of its previously announced underwritten public offering of 16,666,667 of its common shares at a public offering price of $1.50 per share and in lieu of common shares, pre-funded warrants to purchase 3,333,333 common shares at a public offering price of $1.49 per pre-funded warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such pre-funded warrant.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2023.

Orthofix Medical Inc., a leading global spine and orthopedics company, announced the appointment of Jason Shallenberger to President of the Bone Growth Therapies business, and the realignment of its Spine business unit, effective March 1.

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, announced that members of its senior management team will participate at two upcoming investor conferences.

908 Devices Inc. and Cellares announce a development collaboration to integrate in-line monitoring of key cell culture parameters into Cellares’ Cell Shuttle system.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Neurogene Inc. today announced that Company management will participate in the following investor conferences.